Review



polyclonal anti human eno1  (Boster Bio)


Bioz Verified Symbol Boster Bio is a verified supplier
Bioz Manufacturer Symbol Boster Bio manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 92

    Structured Review

    Boster Bio polyclonal anti human eno1
    Expression of <t>ENO1</t> in CRC tissues. (A) Representative immunohistochemical (IHC) images showing in situ ENO1 expression in colorectal cancer (CRC) and normal tissues (scale bar = 100 μm). (B) IHC scores of ENO1 in CRC vs normal tissues. (C) IHC scores of ENO1 in T I-II vs T III-IV tissues. (D–F) Overall survival of CRC patients with high and low expressions (D) of ENO1 with TNM staging I-II (E) and III-IV (F) . Statistical analyses were performed via two-tailed Student t test. ****, P ≤ 0.001.
    Polyclonal Anti Human Eno1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enolase+polyclonal+antibody/Human+Enolase+1%2FNon-neural+enolase+Recombinant+Protein/pmc09813957-82-7-10
    Average 92 stars, based on 4 article reviews
    polyclonal anti human eno1 - by Bioz Stars, 2026-09
    92/100 stars

    Images

    1) Product Images from "ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway"

    Article Title: ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway

    Journal: Frontiers in Oncology

    doi: 10.3389/fonc.2022.1013035

    Expression of ENO1 in CRC tissues. (A) Representative immunohistochemical (IHC) images showing in situ ENO1 expression in colorectal cancer (CRC) and normal tissues (scale bar = 100 μm). (B) IHC scores of ENO1 in CRC vs normal tissues. (C) IHC scores of ENO1 in T I-II vs T III-IV tissues. (D–F) Overall survival of CRC patients with high and low expressions (D) of ENO1 with TNM staging I-II (E) and III-IV (F) . Statistical analyses were performed via two-tailed Student t test. ****, P ≤ 0.001.
    Figure Legend Snippet: Expression of ENO1 in CRC tissues. (A) Representative immunohistochemical (IHC) images showing in situ ENO1 expression in colorectal cancer (CRC) and normal tissues (scale bar = 100 μm). (B) IHC scores of ENO1 in CRC vs normal tissues. (C) IHC scores of ENO1 in T I-II vs T III-IV tissues. (D–F) Overall survival of CRC patients with high and low expressions (D) of ENO1 with TNM staging I-II (E) and III-IV (F) . Statistical analyses were performed via two-tailed Student t test. ****, P ≤ 0.001.

    Techniques Used: Expressing, Immunohistochemical staining, In Situ, Two Tailed Test

    Relationship between  ENO1  and clinic-pathological factors in CRC patients.
    Figure Legend Snippet: Relationship between ENO1 and clinic-pathological factors in CRC patients.

    Techniques Used: Expressing

    Results of univariate and multivariate analyses of postoperative patients’ survival by Cox’s proportional hazard model.
    Figure Legend Snippet: Results of univariate and multivariate analyses of postoperative patients’ survival by Cox’s proportional hazard model.

    Techniques Used:

    Subgroup analysis for the influencing factor of survival among colorectal cancer patients according to ENO1 expression. Statistical analyses were performed via two-tailed Student t test. *, P ≤ 0.05.
    Figure Legend Snippet: Subgroup analysis for the influencing factor of survival among colorectal cancer patients according to ENO1 expression. Statistical analyses were performed via two-tailed Student t test. *, P ≤ 0.05.

    Techniques Used: Expressing, Two Tailed Test

    ENO1 expression was increased in the constructed 5-fluorouracil (FU)-resistant cells. (A) Comparison of ENO1 expression between various CRC cell lines in Cancer Cell Line Encyclopedia (CCLE). (B, C) Immunoblotting results of ENO1 (B) in cell lines HCT116, SW620, HT29, SW480, and LOVO and quantitative counting (C) . (D) Cell viability comparison between HCT116 cells and 5-FU-resistant cells. (E, F) Increase in ENO1 expression (E) in 5-FU-resistant cells and the statistical graph (F) . Statistical analyses were performed via two-tailed Student t test. *,P ≤ 0.05; **,P ≤ 0.01.
    Figure Legend Snippet: ENO1 expression was increased in the constructed 5-fluorouracil (FU)-resistant cells. (A) Comparison of ENO1 expression between various CRC cell lines in Cancer Cell Line Encyclopedia (CCLE). (B, C) Immunoblotting results of ENO1 (B) in cell lines HCT116, SW620, HT29, SW480, and LOVO and quantitative counting (C) . (D) Cell viability comparison between HCT116 cells and 5-FU-resistant cells. (E, F) Increase in ENO1 expression (E) in 5-FU-resistant cells and the statistical graph (F) . Statistical analyses were performed via two-tailed Student t test. *,P ≤ 0.05; **,P ≤ 0.01.

    Techniques Used: Expressing, Construct, Comparison, Western Blot, Two Tailed Test

    Knockdown of ENO1 inhibited the proliferation of 5-fluorouracil (FU)-resistant colorectal cancer (CRC) cells. (A, B) Immunoblots (A) showing ENO1 protein levels in NC and ENO1-KD group and the quantified pattern (B) , reflecting the success of transfection. (C, D) Cell viability of HCT/5-FU (C) and SW620/5-FU (D) cells in the ENO1-KD group and NC group. (E, F) Proliferation rates (E) and colony forming capacity (F) of 5-FU-resistant CRC cells in the ENO1-KD and NC groups (scale bar = 6mm). Statistical analyses were performed via two-tailed Student t test. *,P ≤ 0.05; **,P ≤ 0.01; ***,P ≤ 0.001.
    Figure Legend Snippet: Knockdown of ENO1 inhibited the proliferation of 5-fluorouracil (FU)-resistant colorectal cancer (CRC) cells. (A, B) Immunoblots (A) showing ENO1 protein levels in NC and ENO1-KD group and the quantified pattern (B) , reflecting the success of transfection. (C, D) Cell viability of HCT/5-FU (C) and SW620/5-FU (D) cells in the ENO1-KD group and NC group. (E, F) Proliferation rates (E) and colony forming capacity (F) of 5-FU-resistant CRC cells in the ENO1-KD and NC groups (scale bar = 6mm). Statistical analyses were performed via two-tailed Student t test. *,P ≤ 0.05; **,P ≤ 0.01; ***,P ≤ 0.001.

    Techniques Used: Knockdown, Western Blot, Transfection, Two Tailed Test

    ENO1 knockdown inhibited the migration of resistant cells and was associated with the EMT process. (A–C) Display of representative photographs (A) in the ENO1-KD and NC groups and the number of migration cells in HCT116/5-FU cells (scale bar = 100 μm) (B) and SW620/5-FU cells (C) . (D, F) Western blotting of E-Cadherin, N-Cadherin, and Vimentin expression levels following knockdown of ENO1 in HCT116/5-FU cells (D) and SW620/5-FU cells (F) . (E, G) The bands were quantified and are presented as mean ± SEM of three independent experiments in HCT116/5-FU cells (E) and SW620/5-FU cells (G) . Statistical analyses were performed via two-tailed Student t test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.
    Figure Legend Snippet: ENO1 knockdown inhibited the migration of resistant cells and was associated with the EMT process. (A–C) Display of representative photographs (A) in the ENO1-KD and NC groups and the number of migration cells in HCT116/5-FU cells (scale bar = 100 μm) (B) and SW620/5-FU cells (C) . (D, F) Western blotting of E-Cadherin, N-Cadherin, and Vimentin expression levels following knockdown of ENO1 in HCT116/5-FU cells (D) and SW620/5-FU cells (F) . (E, G) The bands were quantified and are presented as mean ± SEM of three independent experiments in HCT116/5-FU cells (E) and SW620/5-FU cells (G) . Statistical analyses were performed via two-tailed Student t test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.

    Techniques Used: Knockdown, Migration, Western Blot, Expressing, Two Tailed Test

    The regulation of the EMT process by ENO1 is associated with energy metabolism. (A) The morphological changes during the EMT process were suppressed in the ENO1-KD group compared with those in the NC group (observed by light microscope at 200× magnification). (B, C) Western blotting of E-Cadherin, N-Cadherin, and Vimentin expression in NC and ENO1-KD groups treated with or without 20 mM 2-DG for 4 h in HCT116/5-FU cells (B) and SW620/5-FU cells (C) . (D-E) The bands were quantified and are presented as mean ± SEM of three independent experiments in HCT116/5-FU cells (D) and SW620/5-FU cells (E) . Statistical analyses were performed via two-tailed Student t test. **, P ≤ 0.01; ***, P ≤ 0.001. ns, no significance.
    Figure Legend Snippet: The regulation of the EMT process by ENO1 is associated with energy metabolism. (A) The morphological changes during the EMT process were suppressed in the ENO1-KD group compared with those in the NC group (observed by light microscope at 200× magnification). (B, C) Western blotting of E-Cadherin, N-Cadherin, and Vimentin expression in NC and ENO1-KD groups treated with or without 20 mM 2-DG for 4 h in HCT116/5-FU cells (B) and SW620/5-FU cells (C) . (D-E) The bands were quantified and are presented as mean ± SEM of three independent experiments in HCT116/5-FU cells (D) and SW620/5-FU cells (E) . Statistical analyses were performed via two-tailed Student t test. **, P ≤ 0.01; ***, P ≤ 0.001. ns, no significance.

    Techniques Used: Light Microscopy, Western Blot, Expressing, Two Tailed Test

    ENO1 knockdown suppresses tumor growth in colorectal cancer (CRC) in vivo . (A, B) Total body weight and tumor volume in ENO1-KD and NC groups. (C, D) Total body weight and tumor volume in ENO1-KD+5-FU and 5-FU groups. (E) Representative pictures of subcutaneous tumors harvested from the four groups. (F) The weights of tumor masses with or without treatment. (G) Stratification of mice into cluster 1 (grey) and cluster 2 (blue) according to tumor weight and ENO1 levels. (H) Percentage of NC and ENO1-KD mice in each cluster. Statistical analyses were performed via two-tailed Student t test. *, P ≤ 0.05; **, P ≤ 0.01.
    Figure Legend Snippet: ENO1 knockdown suppresses tumor growth in colorectal cancer (CRC) in vivo . (A, B) Total body weight and tumor volume in ENO1-KD and NC groups. (C, D) Total body weight and tumor volume in ENO1-KD+5-FU and 5-FU groups. (E) Representative pictures of subcutaneous tumors harvested from the four groups. (F) The weights of tumor masses with or without treatment. (G) Stratification of mice into cluster 1 (grey) and cluster 2 (blue) according to tumor weight and ENO1 levels. (H) Percentage of NC and ENO1-KD mice in each cluster. Statistical analyses were performed via two-tailed Student t test. *, P ≤ 0.05; **, P ≤ 0.01.

    Techniques Used: Knockdown, In Vivo, Two Tailed Test

    Related Articles

    Incubation:

    Article Title: Injury of cortical neurons is caused by the advanced glycation end products-mediated pathway
    Article Snippet: .. Cells were incubated in rabbit anti-rat neuron-specific enolase polyclonal antibody (1:50; Boster, Wuhan, China) at 37°C for 1 hour, and then left overnight at 4°C overnight. .. Cells were washed in PBS 3 × 5 minutes, incubated in Cy3-labeled goat anti-rabbit IgG (1:400; Boster) at 37°C for 30 minutes, and washed in PBS 3 × 5 minutes.

    Immunostaining:

    Article Title: Effect of early postnatal air-conduction auditory deprivation on the development and function of the rat spiral ganglion
    Article Snippet: Objective: To evaluate the effect of early postnatal air-conduction auditory deprivation on the development and function of the rat spiral ganglion.. Study design: Randomised animal study.. Methods: Sixty neonatal Sprague–Dawley rats were randomly divided into two groups: controls (n= 30) given regular chow and water ad libitum; and study animals (n= 30) fed within a soundproof chamber.



    Similar Products

    92
    Aviva Systems polyclonal rabbit anti enolase
    Polyclonal Rabbit Anti Enolase, supplied by Aviva Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enolase+polyclonal+antibody/Anti-Collagen+Type+II+(RABBIT)+Antibody/pmc12230974-127-15-18
    Average 92 stars, based on 1 article reviews
    polyclonal rabbit anti enolase - by Bioz Stars, 2026-09
    92/100 stars
      Buy from Supplier

    96
    Proteintech rabbit polyclonal anti α enolase
    Rabbit Polyclonal Anti α Enolase, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enolase+polyclonal+antibody/ENO1+Antibody/pm40180688-110-6-11
    Average 96 stars, based on 1 article reviews
    rabbit polyclonal anti α enolase - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    86
    Nichirei Biosciences rabbit polyclonal anti neuron specific enolase antibody
    Rabbit Polyclonal Anti Neuron Specific Enolase Antibody, supplied by Nichirei Biosciences, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enolase+polyclonal+antibody/anti+enolase+neuron+polyclonal+rabbit+specific/pmc12554915-93-13-19
    Average 86 stars, based on 1 article reviews
    rabbit polyclonal anti neuron specific enolase antibody - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    95
    Cell Signaling Technology Inc rabbit polyclonal antibody against flag
    Rabbit Polyclonal Antibody Against Flag, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enolase+polyclonal+antibody/Enolase-1+Antibody/pmc11569218-308-24-22
    Average 95 stars, based on 1 article reviews
    rabbit polyclonal antibody against flag - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    90
    GenScript corporation anti-enolase rabbit polyclonal antibody
    Anti Enolase Rabbit Polyclonal Antibody, supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enolase+polyclonal+antibody/anti+enolase+rabbit+polyclonal+antibody/pm38051052-123-0-6
    Average 90 stars, based on 1 article reviews
    anti-enolase rabbit polyclonal antibody - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    86
    Danaher Inc polyclonal goat anti enolase
    Polyclonal Goat Anti Enolase, supplied by Danaher Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enolase+polyclonal+antibody/pmc10604534-108-22-26
    Average 86 stars, based on 1 article reviews
    polyclonal goat anti enolase - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    92
    Boster Bio polyclonal anti human eno1
    Expression of <t>ENO1</t> in CRC tissues. (A) Representative immunohistochemical (IHC) images showing in situ ENO1 expression in colorectal cancer (CRC) and normal tissues (scale bar = 100 μm). (B) IHC scores of ENO1 in CRC vs normal tissues. (C) IHC scores of ENO1 in T I-II vs T III-IV tissues. (D–F) Overall survival of CRC patients with high and low expressions (D) of ENO1 with TNM staging I-II (E) and III-IV (F) . Statistical analyses were performed via two-tailed Student t test. ****, P ≤ 0.001.
    Polyclonal Anti Human Eno1, supplied by Boster Bio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enolase+polyclonal+antibody/Human+Enolase+1%2FNon-neural+enolase+Recombinant+Protein/pmc09813957-82-7-10
    Average 92 stars, based on 1 article reviews
    polyclonal anti human eno1 - by Bioz Stars, 2026-09
    92/100 stars
      Buy from Supplier

    90
    Santa Cruz Biotechnology affinity purified goat polyclonal anti-α-enolase igg antibody raised against a peptide mapping near the carboxyl-terminus of human α-enolase
    Immunoblot patterns produced by anti-α-enolases and anti-tRNP (Ser)Sec antibodies on electrophoretically separated primate and rat liver homogenates and dot blot results with recombinant tRNP (Ser)Sec . In both rat and primate liver preparations, a band of ~48 kDa is immunofixed by a polyclonal goat IgG <t>anti-α-enolase</t> specific antibody; a band of ~50 kDa is immunofixed by a serum containing a high-titre anti-tRNP (Ser)Sec antibody. Anti-α-enolase antibody does not recognize tRNP (Ser)Sec by dot blot analysis.
    Affinity Purified Goat Polyclonal Anti α Enolase Igg Antibody Raised Against A Peptide Mapping Near The Carboxyl Terminus Of Human α Enolase, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enolase+polyclonal+antibody/affinity+purified+goat+polyclonal+anti+%CE%B1+enolase+igg+antibody+raised+against+a+peptide+mapping+near+the+carboxyl+terminus+of+human+%CE%B1+enolase/pmc00546408-51-17-36
    Average 90 stars, based on 1 article reviews
    affinity purified goat polyclonal anti-α-enolase igg antibody raised against a peptide mapping near the carboxyl-terminus of human α-enolase - by Bioz Stars, 2026-09
    90/100 stars
      Buy from Supplier

    93
    Santa Cruz Biotechnology anti eno2 polyclonal
    Immunoblot patterns produced by anti-α-enolases and anti-tRNP (Ser)Sec antibodies on electrophoretically separated primate and rat liver homogenates and dot blot results with recombinant tRNP (Ser)Sec . In both rat and primate liver preparations, a band of ~48 kDa is immunofixed by a polyclonal goat IgG <t>anti-α-enolase</t> specific antibody; a band of ~50 kDa is immunofixed by a serum containing a high-titre anti-tRNP (Ser)Sec antibody. Anti-α-enolase antibody does not recognize tRNP (Ser)Sec by dot blot analysis.
    Anti Eno2 Polyclonal, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/enolase+polyclonal+antibody/%CE%B3+Enolase+Antibody/pm34037901-44-0-11
    Average 93 stars, based on 1 article reviews
    anti eno2 polyclonal - by Bioz Stars, 2026-09
    93/100 stars
      Buy from Supplier

    Image Search Results


    Expression of ENO1 in CRC tissues. (A) Representative immunohistochemical (IHC) images showing in situ ENO1 expression in colorectal cancer (CRC) and normal tissues (scale bar = 100 μm). (B) IHC scores of ENO1 in CRC vs normal tissues. (C) IHC scores of ENO1 in T I-II vs T III-IV tissues. (D–F) Overall survival of CRC patients with high and low expressions (D) of ENO1 with TNM staging I-II (E) and III-IV (F) . Statistical analyses were performed via two-tailed Student t test. ****, P ≤ 0.001.

    Journal: Frontiers in Oncology

    Article Title: ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway

    doi: 10.3389/fonc.2022.1013035

    Figure Lengend Snippet: Expression of ENO1 in CRC tissues. (A) Representative immunohistochemical (IHC) images showing in situ ENO1 expression in colorectal cancer (CRC) and normal tissues (scale bar = 100 μm). (B) IHC scores of ENO1 in CRC vs normal tissues. (C) IHC scores of ENO1 in T I-II vs T III-IV tissues. (D–F) Overall survival of CRC patients with high and low expressions (D) of ENO1 with TNM staging I-II (E) and III-IV (F) . Statistical analyses were performed via two-tailed Student t test. ****, P ≤ 0.001.

    Article Snippet: The sections were incubated with 1:100 diluted polyclonal anti-human ENO1 (BOSTER, Wuhan, China) at 4°C overnight.

    Techniques: Expressing, Immunohistochemical staining, In Situ, Two Tailed Test

    Relationship between  ENO1  and clinic-pathological factors in CRC patients.

    Journal: Frontiers in Oncology

    Article Title: ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway

    doi: 10.3389/fonc.2022.1013035

    Figure Lengend Snippet: Relationship between ENO1 and clinic-pathological factors in CRC patients.

    Article Snippet: The sections were incubated with 1:100 diluted polyclonal anti-human ENO1 (BOSTER, Wuhan, China) at 4°C overnight.

    Techniques: Expressing

    Results of univariate and multivariate analyses of postoperative patients’ survival by Cox’s proportional hazard model.

    Journal: Frontiers in Oncology

    Article Title: ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway

    doi: 10.3389/fonc.2022.1013035

    Figure Lengend Snippet: Results of univariate and multivariate analyses of postoperative patients’ survival by Cox’s proportional hazard model.

    Article Snippet: The sections were incubated with 1:100 diluted polyclonal anti-human ENO1 (BOSTER, Wuhan, China) at 4°C overnight.

    Techniques:

    Subgroup analysis for the influencing factor of survival among colorectal cancer patients according to ENO1 expression. Statistical analyses were performed via two-tailed Student t test. *, P ≤ 0.05.

    Journal: Frontiers in Oncology

    Article Title: ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway

    doi: 10.3389/fonc.2022.1013035

    Figure Lengend Snippet: Subgroup analysis for the influencing factor of survival among colorectal cancer patients according to ENO1 expression. Statistical analyses were performed via two-tailed Student t test. *, P ≤ 0.05.

    Article Snippet: The sections were incubated with 1:100 diluted polyclonal anti-human ENO1 (BOSTER, Wuhan, China) at 4°C overnight.

    Techniques: Expressing, Two Tailed Test

    ENO1 expression was increased in the constructed 5-fluorouracil (FU)-resistant cells. (A) Comparison of ENO1 expression between various CRC cell lines in Cancer Cell Line Encyclopedia (CCLE). (B, C) Immunoblotting results of ENO1 (B) in cell lines HCT116, SW620, HT29, SW480, and LOVO and quantitative counting (C) . (D) Cell viability comparison between HCT116 cells and 5-FU-resistant cells. (E, F) Increase in ENO1 expression (E) in 5-FU-resistant cells and the statistical graph (F) . Statistical analyses were performed via two-tailed Student t test. *,P ≤ 0.05; **,P ≤ 0.01.

    Journal: Frontiers in Oncology

    Article Title: ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway

    doi: 10.3389/fonc.2022.1013035

    Figure Lengend Snippet: ENO1 expression was increased in the constructed 5-fluorouracil (FU)-resistant cells. (A) Comparison of ENO1 expression between various CRC cell lines in Cancer Cell Line Encyclopedia (CCLE). (B, C) Immunoblotting results of ENO1 (B) in cell lines HCT116, SW620, HT29, SW480, and LOVO and quantitative counting (C) . (D) Cell viability comparison between HCT116 cells and 5-FU-resistant cells. (E, F) Increase in ENO1 expression (E) in 5-FU-resistant cells and the statistical graph (F) . Statistical analyses were performed via two-tailed Student t test. *,P ≤ 0.05; **,P ≤ 0.01.

    Article Snippet: The sections were incubated with 1:100 diluted polyclonal anti-human ENO1 (BOSTER, Wuhan, China) at 4°C overnight.

    Techniques: Expressing, Construct, Comparison, Western Blot, Two Tailed Test

    Knockdown of ENO1 inhibited the proliferation of 5-fluorouracil (FU)-resistant colorectal cancer (CRC) cells. (A, B) Immunoblots (A) showing ENO1 protein levels in NC and ENO1-KD group and the quantified pattern (B) , reflecting the success of transfection. (C, D) Cell viability of HCT/5-FU (C) and SW620/5-FU (D) cells in the ENO1-KD group and NC group. (E, F) Proliferation rates (E) and colony forming capacity (F) of 5-FU-resistant CRC cells in the ENO1-KD and NC groups (scale bar = 6mm). Statistical analyses were performed via two-tailed Student t test. *,P ≤ 0.05; **,P ≤ 0.01; ***,P ≤ 0.001.

    Journal: Frontiers in Oncology

    Article Title: ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway

    doi: 10.3389/fonc.2022.1013035

    Figure Lengend Snippet: Knockdown of ENO1 inhibited the proliferation of 5-fluorouracil (FU)-resistant colorectal cancer (CRC) cells. (A, B) Immunoblots (A) showing ENO1 protein levels in NC and ENO1-KD group and the quantified pattern (B) , reflecting the success of transfection. (C, D) Cell viability of HCT/5-FU (C) and SW620/5-FU (D) cells in the ENO1-KD group and NC group. (E, F) Proliferation rates (E) and colony forming capacity (F) of 5-FU-resistant CRC cells in the ENO1-KD and NC groups (scale bar = 6mm). Statistical analyses were performed via two-tailed Student t test. *,P ≤ 0.05; **,P ≤ 0.01; ***,P ≤ 0.001.

    Article Snippet: The sections were incubated with 1:100 diluted polyclonal anti-human ENO1 (BOSTER, Wuhan, China) at 4°C overnight.

    Techniques: Knockdown, Western Blot, Transfection, Two Tailed Test

    ENO1 knockdown inhibited the migration of resistant cells and was associated with the EMT process. (A–C) Display of representative photographs (A) in the ENO1-KD and NC groups and the number of migration cells in HCT116/5-FU cells (scale bar = 100 μm) (B) and SW620/5-FU cells (C) . (D, F) Western blotting of E-Cadherin, N-Cadherin, and Vimentin expression levels following knockdown of ENO1 in HCT116/5-FU cells (D) and SW620/5-FU cells (F) . (E, G) The bands were quantified and are presented as mean ± SEM of three independent experiments in HCT116/5-FU cells (E) and SW620/5-FU cells (G) . Statistical analyses were performed via two-tailed Student t test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.

    Journal: Frontiers in Oncology

    Article Title: ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway

    doi: 10.3389/fonc.2022.1013035

    Figure Lengend Snippet: ENO1 knockdown inhibited the migration of resistant cells and was associated with the EMT process. (A–C) Display of representative photographs (A) in the ENO1-KD and NC groups and the number of migration cells in HCT116/5-FU cells (scale bar = 100 μm) (B) and SW620/5-FU cells (C) . (D, F) Western blotting of E-Cadherin, N-Cadherin, and Vimentin expression levels following knockdown of ENO1 in HCT116/5-FU cells (D) and SW620/5-FU cells (F) . (E, G) The bands were quantified and are presented as mean ± SEM of three independent experiments in HCT116/5-FU cells (E) and SW620/5-FU cells (G) . Statistical analyses were performed via two-tailed Student t test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001.

    Article Snippet: The sections were incubated with 1:100 diluted polyclonal anti-human ENO1 (BOSTER, Wuhan, China) at 4°C overnight.

    Techniques: Knockdown, Migration, Western Blot, Expressing, Two Tailed Test

    The regulation of the EMT process by ENO1 is associated with energy metabolism. (A) The morphological changes during the EMT process were suppressed in the ENO1-KD group compared with those in the NC group (observed by light microscope at 200× magnification). (B, C) Western blotting of E-Cadherin, N-Cadherin, and Vimentin expression in NC and ENO1-KD groups treated with or without 20 mM 2-DG for 4 h in HCT116/5-FU cells (B) and SW620/5-FU cells (C) . (D-E) The bands were quantified and are presented as mean ± SEM of three independent experiments in HCT116/5-FU cells (D) and SW620/5-FU cells (E) . Statistical analyses were performed via two-tailed Student t test. **, P ≤ 0.01; ***, P ≤ 0.001. ns, no significance.

    Journal: Frontiers in Oncology

    Article Title: ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway

    doi: 10.3389/fonc.2022.1013035

    Figure Lengend Snippet: The regulation of the EMT process by ENO1 is associated with energy metabolism. (A) The morphological changes during the EMT process were suppressed in the ENO1-KD group compared with those in the NC group (observed by light microscope at 200× magnification). (B, C) Western blotting of E-Cadherin, N-Cadherin, and Vimentin expression in NC and ENO1-KD groups treated with or without 20 mM 2-DG for 4 h in HCT116/5-FU cells (B) and SW620/5-FU cells (C) . (D-E) The bands were quantified and are presented as mean ± SEM of three independent experiments in HCT116/5-FU cells (D) and SW620/5-FU cells (E) . Statistical analyses were performed via two-tailed Student t test. **, P ≤ 0.01; ***, P ≤ 0.001. ns, no significance.

    Article Snippet: The sections were incubated with 1:100 diluted polyclonal anti-human ENO1 (BOSTER, Wuhan, China) at 4°C overnight.

    Techniques: Light Microscopy, Western Blot, Expressing, Two Tailed Test

    ENO1 knockdown suppresses tumor growth in colorectal cancer (CRC) in vivo . (A, B) Total body weight and tumor volume in ENO1-KD and NC groups. (C, D) Total body weight and tumor volume in ENO1-KD+5-FU and 5-FU groups. (E) Representative pictures of subcutaneous tumors harvested from the four groups. (F) The weights of tumor masses with or without treatment. (G) Stratification of mice into cluster 1 (grey) and cluster 2 (blue) according to tumor weight and ENO1 levels. (H) Percentage of NC and ENO1-KD mice in each cluster. Statistical analyses were performed via two-tailed Student t test. *, P ≤ 0.05; **, P ≤ 0.01.

    Journal: Frontiers in Oncology

    Article Title: ENO1 contributes to 5-fluorouracil resistance in colorectal cancer cells via EMT pathway

    doi: 10.3389/fonc.2022.1013035

    Figure Lengend Snippet: ENO1 knockdown suppresses tumor growth in colorectal cancer (CRC) in vivo . (A, B) Total body weight and tumor volume in ENO1-KD and NC groups. (C, D) Total body weight and tumor volume in ENO1-KD+5-FU and 5-FU groups. (E) Representative pictures of subcutaneous tumors harvested from the four groups. (F) The weights of tumor masses with or without treatment. (G) Stratification of mice into cluster 1 (grey) and cluster 2 (blue) according to tumor weight and ENO1 levels. (H) Percentage of NC and ENO1-KD mice in each cluster. Statistical analyses were performed via two-tailed Student t test. *, P ≤ 0.05; **, P ≤ 0.01.

    Article Snippet: The sections were incubated with 1:100 diluted polyclonal anti-human ENO1 (BOSTER, Wuhan, China) at 4°C overnight.

    Techniques: Knockdown, In Vivo, Two Tailed Test

    Immunoblot patterns produced by anti-α-enolases and anti-tRNP (Ser)Sec antibodies on electrophoretically separated primate and rat liver homogenates and dot blot results with recombinant tRNP (Ser)Sec . In both rat and primate liver preparations, a band of ~48 kDa is immunofixed by a polyclonal goat IgG anti-α-enolase specific antibody; a band of ~50 kDa is immunofixed by a serum containing a high-titre anti-tRNP (Ser)Sec antibody. Anti-α-enolase antibody does not recognize tRNP (Ser)Sec by dot blot analysis.

    Journal: Journal of Autoimmune Diseases

    Article Title: Antibodies to soluble liver antigen and α-enolase in patients with autoimmune hepatitis

    doi: 10.1186/1740-2557-1-4

    Figure Lengend Snippet: Immunoblot patterns produced by anti-α-enolases and anti-tRNP (Ser)Sec antibodies on electrophoretically separated primate and rat liver homogenates and dot blot results with recombinant tRNP (Ser)Sec . In both rat and primate liver preparations, a band of ~48 kDa is immunofixed by a polyclonal goat IgG anti-α-enolase specific antibody; a band of ~50 kDa is immunofixed by a serum containing a high-titre anti-tRNP (Ser)Sec antibody. Anti-α-enolase antibody does not recognize tRNP (Ser)Sec by dot blot analysis.

    Article Snippet: An affinity purified goat polyclonal anti-α-enolase IgG antibody raised against a peptide mapping near the carboxyl-terminus of human α-enolase, which is common to α, β, and γ isoforms of mouse, rat and human enolase (200 μg/ml; Santa Cruz Biotechnology, Santa Cruz, California, USA) was used as reference serum sample at a dilution of 1:100, according to the manufacturer's instructions.

    Techniques: Western Blot, Produced, Dot Blot, Recombinant

    Immunoblot patterns produced on rat liver homogenate by (lane 1) a polyclonal goat IgG anti-α-enolase specific antibody; (lanes 2–5) four representative anti-soluble liver antigen (SLA) positive sera; (lane 6) a reference serum containing high-titre anti-tRNP (Ser)Sec antibody.

    Journal: Journal of Autoimmune Diseases

    Article Title: Antibodies to soluble liver antigen and α-enolase in patients with autoimmune hepatitis

    doi: 10.1186/1740-2557-1-4

    Figure Lengend Snippet: Immunoblot patterns produced on rat liver homogenate by (lane 1) a polyclonal goat IgG anti-α-enolase specific antibody; (lanes 2–5) four representative anti-soluble liver antigen (SLA) positive sera; (lane 6) a reference serum containing high-titre anti-tRNP (Ser)Sec antibody.

    Article Snippet: An affinity purified goat polyclonal anti-α-enolase IgG antibody raised against a peptide mapping near the carboxyl-terminus of human α-enolase, which is common to α, β, and γ isoforms of mouse, rat and human enolase (200 μg/ml; Santa Cruz Biotechnology, Santa Cruz, California, USA) was used as reference serum sample at a dilution of 1:100, according to the manufacturer's instructions.

    Techniques: Western Blot, Produced

    Immunoblot patterns obtained using 9 SLA positive and 9 SLA negative serum samples against recombinant α-enolase. A polyclonal goat IgG anti-α-enolase specific antibody has been used as a reference positive serum. Ab, antibody; ag, antigen

    Journal: Journal of Autoimmune Diseases

    Article Title: Antibodies to soluble liver antigen and α-enolase in patients with autoimmune hepatitis

    doi: 10.1186/1740-2557-1-4

    Figure Lengend Snippet: Immunoblot patterns obtained using 9 SLA positive and 9 SLA negative serum samples against recombinant α-enolase. A polyclonal goat IgG anti-α-enolase specific antibody has been used as a reference positive serum. Ab, antibody; ag, antigen

    Article Snippet: An affinity purified goat polyclonal anti-α-enolase IgG antibody raised against a peptide mapping near the carboxyl-terminus of human α-enolase, which is common to α, β, and γ isoforms of mouse, rat and human enolase (200 μg/ml; Santa Cruz Biotechnology, Santa Cruz, California, USA) was used as reference serum sample at a dilution of 1:100, according to the manufacturer's instructions.

    Techniques: Western Blot, Recombinant